MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability

Poster presentation highlights SMART adenine base editors (ABEs)
small enough to be packaged into a single adeno-associated virus (AAV)

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan's 8th Annual Genetic Medicines Conference:

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci

EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences:

Declared development candidate MGX-001 for the treatment of hemophilia A;
plans to present 12-month NHP durability study data in September 2024